LGND – ligand pharmaceuticals incorporated (US:NASDAQ)
Stock Stats
News
Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a "buy" rating on the stock.
Ligand Pharmaceuticals (LGND) had its price target raised by HC Wainwright from $239.00 to $243.00. They now have a "buy" rating on the stock.
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year [Yahoo! Finance]
CLO Sells LGND 5,000 Shares for $1.0 Million [Yahoo! Finance]
Form 4 LIGAND PHARMACEUTICALS For: Apr 01 Filed by: KOZARICH JOHN W
Form 4 LIGAND PHARMACEUTICALS For: Apr 01 Filed by: Reardon Andrew
Form 144 LIGAND PHARMACEUTICALS Filed by: KOZARICH JOHN W
Form 4 LIGAND PHARMACEUTICALS For: Mar 06 Filed by: LAMATTINA JOHN L
Form 4 LIGAND PHARMACEUTICALS For: Mar 02 Filed by: Espinoza Octavio
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.